公开(公告)号：US20190023657A1

公开(公告)日：2019-01-24

申请号：US16138369

申请日：2018-09-21

Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.

Inventor： Fumihiko SAITOH ,  Hiroshi NAGASUE

IPC: C07D213/75 ,  A61K45/06 ,  A61K31/4418 ,  C07D401/04 ,  A61K31/506 ,  A61K31/4439 ,  A61K31/444 ,  C07D213/84 ,  C07D405/04 ,  A61K31/4433 ,  C07D405/14 ,  C07D213/81 ,  C07D413/12 ,  C07D417/04

CPC classification number: C07D213/75 ,  A61K31/4418 ,  A61K31/4433 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/506 ,  A61K45/06 ,  A61P1/00 ,  A61P1/02 ,  A61P1/04 ,  A61P1/16 ,  A61P1/18 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10 ,  A61P5/14 ,  A61P7/00 ,  A61P9/00 ,  A61P9/06 ,  A61P9/12 ,  A61P11/00 ,  A61P11/02 ,  A61P11/04 ,  A61P11/06 ,  A61P13/02 ,  A61P13/08 ,  A61P13/10 ,  A61P13/12 ,  A61P15/00 ,  A61P17/00 ,  A61P19/02 ,  A61P19/10 ,  A61P21/00 ,  A61P21/02 ,  A61P25/00 ,  A61P25/04 ,  A61P25/08 ,  A61P25/16 ,  A61P25/20 ,  A61P25/24 ,  A61P25/28 ,  A61P29/00 ,  A61P29/02 ,  A61P31/00 ,  A61P31/18 ,  A61P35/00 ,  A61P35/02 ,  A61P37/00 ,  A61P37/06 ,  A61P43/00 ,  C07B2200/07 ,  C07C215/44 ,  C07C271/24 ,  C07C2602/10 ,  C07D213/81 ,  C07D213/84 ,  C07D401/04 ,  C07D405/04 ,  C07D405/14 ,  C07D413/12 ,  C07D417/04

Abstract: The present invention aims to provide a compound having a TrkA inhibitory action, a pharmaceutically acceptable salt thereof, or a solvate thereof, a pharmaceutical composition containing the same as an active ingredient, and a preventive and/or therapeutic agent for medicinal use, in particular for a disease in which TrkA in involved (pain, cancers, inflammation/inflammatory diseases, allergic diseases, skin diseases, neurodegenerative diseases, infectious diseases, Sjogren's syndrome, endometriosis, renal diseases, osteoporosis, and the like). Specifically, the present invention provides a compound or an optical isomer thereof, a pharmaceutically acceptable salt thereof, a solvate thereof, or the like, the compound represented by formula (I):

公开(公告)号：US20180235874A1

公开(公告)日：2018-08-23

申请号：US15851225

申请日：2017-12-21

Applicant: Gina Bassile Hickham

Inventor： Gina Bassile Hickham

IPC: A61K9/00 ,  A61K47/42 ,  A61K36/889 ,  A61P11/04 ,  A61K31/70 ,  A61P31/04 ,  A61K35/644

CPC classification number: A61K9/0056 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2068 ,  A61K31/70 ,  A61K35/644 ,  A61K36/889 ,  A61K47/42 ,  A61P11/04 ,  A61P31/04 ,  A61K2300/00

Abstract: This organic lozenge may be beneficial to individuals with allergies, sore throat, dry mouth, colds and/or flu based on the many scientific benefits of coconut oil and honey. These benefits include reduced inflammation, anti-bacterial and viral properties, which help fight illness. The physical properties of coconut oil and honey are known to suppress a cough and moisturize the mouth and throat.

公开(公告)号：US20240124408A1

公开(公告)日：2024-04-18

申请号：US18267644

申请日：2021-12-16

Applicant: Sanofi

Inventor： Paul Justin Mueller ,  Florian Auger ,  Guillaume Begis ,  Yann Foricher ,  Christoph Grebner ,  Stéphane Hourcade ,  Stéphanie Meyfroot ,  Sven Ruf ,  Klaus Wirth

IPC: C07D305/06 ,  A61P11/04 ,  C07C235/40 ,  C07C237/12

CPC classification number: C07D305/06 ,  A61P11/04 ,  C07C235/40 ,  C07C237/12

Abstract: Compounds of formula (1):




wherein R1 represents a —C(R2)(R3)—[C(R4)(R5)]m-L-R6 group or —R7; and the preparation and the therapeutic uses of the compounds of formula (1) as agonists of TRPM8 receptors, useful especially in the treatment of oropharyngeal dysphagia.

公开(公告)号：US20240000767A1

公开(公告)日：2024-01-04

申请号：US18014664

申请日：2021-07-05

Applicant: Bayer Aktiengesellschaft

Inventor： Martina DELBECK ,  Michael HAHN

IPC: A61K31/4545 ,  A61P11/04 ,  A61K31/55 ,  A61K31/4439

CPC classification number: A61K31/4545 ,  A61K31/4439 ,  A61K31/55 ,  A61P11/04

Abstract: The present invention relates to a combination of selective blockers of TASK-1 and TASK-3 channels, in particular substituted imidazo [1,2-a]pyrimidine and substituted imidazo [1,2-a]pyridine derivatives of formula (II) and α2-Adrenoceptor subtype C (alpha-2C) antagonists, in particular substituted heterocyclic carboxamides of formula (I) for the treatment and/or prophylaxis of sleep-related breathing disorders, preferably obstructive and central sleep apneas and snoring.

公开(公告)号：US20240358709A1

公开(公告)日：2024-10-31

申请号：US18687660

申请日：2022-08-30

Applicant: APNIMED, INC. (DELAWARE)

Inventor： David P. WHITE ,  Luigi TARANTO-MONTEMURRO ,  Ronald FARKAS ,  Lawrence G. MILLER

IPC: A61K31/5375 ,  A61F5/56 ,  A61K31/138 ,  A61K31/216 ,  A61K31/437 ,  A61K31/496 ,  A61P11/04

CPC classification number: A61K31/5375 ,  A61F5/566 ,  A61K31/138 ,  A61K31/216 ,  A61K31/437 ,  A61K31/496 ,  A61P11/04

Abstract: Methods of treating pharyngeal airway collapse (e.g., sleep apnea) by administering a norepinephrine reuptake inhibitor (NRI) in combination with mandibular advancement device (MAD) therapy are described herein. The treatment may further comprise administration of a muscarinic receptor antagonist (MRA) and/or a hypnotic.

公开(公告)号：US20240189328A1

公开(公告)日：2024-06-13

申请号：US18286399

申请日：2022-04-15

Applicant: APNIMED, INC. (DELAWARE)

Inventor： Lawrence G. MILLER ,  Luigi TARANTO-MONTEMURRO ,  Ronald FARKAS ,  David P. WHITE

IPC: A61K31/00 ,  A61K31/138 ,  A61K31/216 ,  A61K31/433 ,  A61K31/5375 ,  A61P11/04

CPC classification number: A61K31/658 ,  A61K31/138 ,  A61K31/216 ,  A61K31/433 ,  A61K31/5375 ,  A61P11/04

Abstract: Pharmaceutical compositions comprising a norepinephrine reuptake inhibitor (NRI) and a cannabinoid and optionally a muscarinic receptor antagonist (MRA) and/or carbonic anhydrase inhibitor (CAI) and methods of treating sleep apnea are described herein.

公开(公告)号：US20240277719A1

公开(公告)日：2024-08-22

申请号：US18570673

申请日：2022-06-17

Applicant: APNIMED, INC. (DELAWARE)

Inventor： Luigi TARANTO-MONTEMURRO ,  Ronald FARKAS ,  David P. WHITE ,  Lawrence G. MILLER

IPC: A61K31/5375 ,  A61K9/00 ,  A61K31/216 ,  A61K31/496 ,  A61K31/5377 ,  A61P11/04

CPC classification number: A61K31/5375 ,  A61K9/0053 ,  A61K31/216 ,  A61K31/496 ,  A61K31/5377 ,  A61P11/04

Abstract: Methods of treating sleep apnea and snoring comprising administering a norepinephrine reuptake inhibitor, optionally in the absence of an antimuscarinic agent, and optionally as a monotherapy, are described herein. Pharmaceutical compositions comprising norepinephrine reuptake inhibitors, such as edivoxetine and viloxazine, are also described.

公开(公告)号：US20240226139A9

公开(公告)日：2024-07-11

申请号：US18382179

申请日：2023-10-20

Applicant: Graceful Caring Hands, Inc.

Inventor： Olukunle Jacob Adebiyi

IPC: A61K33/00 ,  A61K9/00 ,  A61K9/08 ,  A61K31/09 ,  A61K31/495 ,  A61P11/02 ,  A61P11/04

CPC classification number: A61K33/00 ,  A61K9/0043 ,  A61K9/0056 ,  A61K9/0095 ,  A61K9/08 ,  A61K31/09 ,  A61K31/495 ,  A61P11/02 ,  A61P11/04

Abstract: A dosing regimen for administering a composition to a patient for treatment of congestion or irritation includes administering a first dose of the composition to the patient. The composition is formulated as an aqueous solution including between about 0.125 to about 1 milliequivalents of sodium bicarbonate per milliliter of the aqueous solution. The first dose includes between about 0.25 to about 1 milliliter of the composition. The dosing regimen also includes administering a second dose of the composition to the patient after administration of the first dose. The second dose includes between about 0.25 to about 1 milliliter of the composition.

公开(公告)号：US20230218724A1

公开(公告)日：2023-07-13

申请号：US18010762

申请日：2021-06-15

Applicant: JELLAGEN PTY LTD ,  MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH

Inventor： Andrew Mearns SPRAGG ,  Dale EKBOM ,  Serban SAN-MARINA

IPC: A61K38/39 ,  A61K35/28 ,  A61P11/04

CPC classification number: A61K38/39 ,  A61K35/28 ,  A61P11/04

Abstract: The present invention relates to jellyfish collagen for use in the treatment of vocal fold paralysis.

公开(公告)号：US20240261359A1

公开(公告)日：2024-08-08

申请号：US18026851

申请日：2021-06-24

Applicant: Tianjin University of Traditional Chinese Medicine

Inventor： Boli Zhang ,  Junhua Zhang ,  Xinbo Song ,  Han Zhang ,  Lin Miao ,  Kun Zhou ,  Ming Ren ,  Erwei Liu ,  Yuefei Wang ,  Wenke Zheng ,  Fengwen Yang

IPC: A61K36/734 ,  A61K36/28 ,  A61K36/346 ,  A61K36/355 ,  A61K36/481 ,  A61K36/484 ,  A61K36/535 ,  A61K36/65 ,  A61P11/04

CPC classification number: A61K36/734 ,  A61K36/28 ,  A61K36/346 ,  A61K36/355 ,  A61K36/481 ,  A61K36/484 ,  A61K36/535 ,  A61K36/65 ,  A61P11/04

Abstract: The present invention relates to a pharmaceutical composition for use preventing and curing respiratory diseases in winter. The composition comprises burdock seeds, blackberry lily, Platycodon grandiflorus, radix paeoniae rubra, Perilla frutescens, honeysuckle, fructus crataegi, Astragalus membranaceus, Reynoutria japonica, Glycyrrhiza uralensis, and non-essential fermented tea. The present invention also relates to a pharmaceutical preparation use of the pharmaceutical composition. The pharmaceutical composition can be used for nourishing Qi, moistening lungs, clearing throats, relieving sore throats and/or decontaminating, and can be used for preparing a pharmaceutical for treating and/or preventing pharyngitis.